Evidence map›Paper›PMID 42015618›Full record

ArticleAnnals of clinical and translational neurology2026

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined Synucleinopathy.

Daniel Weintraub, Michele K York, Roseanne Dobkin, Anuprita R Nair, Ryan Kurth, David-Erick Lafontant, Chelsea Caspell-Garcia, Roy N Alcalay, Ethan G Brown, Lana M Chahine and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Daniel WeintraubDepartment of Psychiatry and Neurology, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0633-7168
Michele K YorkDepartment of Neurology, Baylor College of Medicine, Houston, Texas, USA.
Roseanne DobkinDepartment of Psychiatry, Rutgers University, New Brunswick, New Jersey, USA.
Anuprita R NairDepartment of Biostatistics, University of Iowa, Iowa City, Iowa, USA.
Ryan KurthDepartment of Biostatistics, University of Iowa, Iowa City, Iowa, USA.
David-Erick LafontantDepartment of Biostatistics, University of Iowa, Iowa City, Iowa, USA.
Chelsea Caspell-GarciaDepartment of Biostatistics, University of Iowa, Iowa City, Iowa, USA.
Roy N AlcalayMovement Disorders Division, Tel Aviv Sourasky Medical Center; Tel Aviv, Israel, Columbia University Irving Medical Center, New York, New York, USA.
Ethan G BrownDepartment of Neurology, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-9744-8562
Lana M ChahineDepartment of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Christopher CoffeyDepartment of Biostatistics, University of Iowa, Iowa City, Iowa, USA.
Tatiana ForoudDepartment of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana, USA.
Douglas GalaskoDepartment of Neurosciences, University of California, San Diego, California, USA.
Karl KieburtzDepartment of Neurology, University of Rochester, Rochester, New York, USA.
Kenneth MarekInstitute for Neurodegenerative Disorders, New Haven, Connecticut, USA.
Kalpana MerchantDepartment of Neurology, Northwestern University, Chicago, Illinois, USA.
Brit MollenhauerDepartment of Neurology, University Medical Center Göttingen, Kassel, Göttingen, Germany.
Kathleen L PostonDepartment of Neurology, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0003-3424-7143
Andrew SiderowfDepartment of Psychiatry and Neurology, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Cristina SimonetCentre for Preventive Neurology, Wolfson Institute for Population Health, Queen Mary University of London, London, UK.
Tanya SimuniDepartment of Neurology, Northwestern University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-2347-1644
Caroline M TannerDepartment of Neurology, University of California San Francisco, San Francisco, California, USA.
Thomas F TropeaInstitute for Neurodegenerative Disorders, New Haven, Connecticut, USA.
Aleksandar VidenovicDivision of Sleep Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Parkinson's Progression Markers Initiative

Funding

Michael J. Fox Foundation for Parkinson's Research Parkinson's Progression Markers Initiative
6 · The paper itself

Abstract

objectiveIsolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker-defined synucleinopathy.

methodsParkinson's Progression Markers Initiative (PPMI) is a longitudinal, multi-center observational study. Participants included polysomnogram (PSG)-confirmed iRBD individuals who were cerebrospinal fluid (CSF) α-synuclein seed amplification assay positive with no clinical diagnosis of Parkinson's disease or dementia with Lewy bodies, along with robust healthy controls (HCs). Clinical and biological features of prodromal PD and DLB, including mild cognitive impairment (MCI), subthreshold parkinsonism, and a range of neuropsychiatric, autonomic, and sensory symptoms, were assessed.

resultsCompared with HCs (N = 136), iRBD participants (N = 197) demonstrated worse cognitive performance, including a lower cognitive summary score (p < 0.0003, effect size = 0.41), and higher odds of subthreshold parkinsonism (OR = 24.5), and neuropsychiatric (OR = 3.5), autonomic (OR = 7.2) and sensory symptoms (OR = 13.2). Common features included hyposmia (75%), pain (54%), urinary problems (52%), constipation (49%), lightheadedness (40%) and anxiety (36%), whereas rates of MCI (32%), subthreshold parkinsonism (27%) and psychosis (7%) were lower. iRBD participants with abnormal dopamine transporter imaging had higher anxiety scores and antidepressant use. Although only 10% met criteria for prodromal DLB due to the requirement for MCI, most exhibited multi-domain impairment.

interpretationiRBD with synucleinopathy is associated with multi-domain clinical impairment before clinical neurodegenerative disease diagnosis, supporting broad clinical assessment in early biomarker-defined synuclein disease.

Indexed as

autonomicdementiamild cognitive impairmentneuropsychiatricRBD

Identifiers

PMID42015618
PMCPMC13394823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.